Literature DB >> 12052667

Clinical toxicological aspects of fluoroquinolones.

Ralf Stahlmann1.   

Abstract

Reactions of the gastrointestinal tract and the central nervous system are the most often observed adverse effects during therapy with fluoroquinolones. Pathogenesis of the neurotoxic effects of fluoroquinolones could be related to the activation of the NMDA receptor. Animal experiments as well as clinical experience show that the cardiotoxic potentials of sparfloxacin and grepafloxacin are higher than those of the other fluoroquinolones: they cause QT prolongation at rather low doses thus increasing the risk for severe arrhythmia (torsades de pointes). Phototoxicity has been described for all quinolones, but derivatives with a halogen atom at position 8 show the highest potential for such reactions (e.g. clinafloxacin). Chondrotoxicity of quinolones can affect the articular cartilage and the epiphyseal growth plate in immature animals; the use of these drugs in pediatrics should be restricted to carefully selected indications (such as the use of ciprofloxacin in cystic fibrosis). Tendinitis and tendon ruptures can also be induced by quinolones. Overall, quinolones are as well tolerated as most other anti-microbial agents. However, their specific toxic potentials have to be considered when they are chosen for treatment of bacterial infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052667     DOI: 10.1016/s0378-4274(01)00509-4

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  24 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

Review 2.  [Sense and nonsense in antibiotic therapy for respiratory tract infections].

Authors:  W Domej; E Flögel; G P Tilz; U Demel
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

Review 3.  Bilateral plantar tendinitis during levofloxacin therapy.

Authors:  Jan Beyer; Sebastian Schellong
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

4.  Levofloxacin-induced taste perversion, blurred vision and dyspnoea in a young woman.

Authors:  Luca Gallelli; Serena Del Negro; Saverio Naty; Manuela Colosimo; Rosario Maselli; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Clinical and histopathologic features of fluoroquinolone-induced liver injury.

Authors:  Eric S Orman; Hari S Conjeevaram; Raj Vuppalanchi; James W Freston; James Rochon; David E Kleiner; Paul H Hayashi
Journal:  Clin Gastroenterol Hepatol       Date:  2011-02-26       Impact factor: 11.382

6.  Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats.

Authors:  Eva Maria Kappel; Mehdi Shakibaei; Akintunde Bello; Ralf Stahlmann
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 7.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.

Authors:  M Solèr; H Lode; R Baldwin; J H A Levine; A J M Schreurs; J A van Noord; F P V Maesen; M Zehrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

9.  Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.

Authors:  David T Chung; Cheng-Yuan Tsai; Shu-Jen Chen; Li-Wen Chang; Chi-Hsin R King; Ching-Hung Hsu; Kit-Mui Chiu; Hao-Chen Tan; Yu-Ting Chang; Ming-Chu Hsu
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

10.  Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.

Authors:  Luke Lin; Li-Wen Chang; Cheng-Yuan Tsai; Ching-Hung Hsu; David T Chung; William S Aronstein; Funmi Ajayi; Barbara Kuzmak; Robert A Lyon
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.